Zydus Cadila’s Nesher Pharmaceuticals has received final approval from the United States Food and Drug Administration (USFDA) to market Oseltamivir Powder for Oral Suspension, 6 mg/ml which is used in the treatment and prevention of influenza.
It will be produced at the Nesher Pharmaceuticals’ manufacturing facility located at St. Louis, MO, USA. The sales of Oseltamivir Powder for Oral Suspension are estimated at $367.92 million.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group now has more than 150 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.
